TAK-075 | CAS#667931-33-1 | biochemical

MedKoo Cat#: 145751 | Name: TAK-075

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TAK-075 is an investigational drug developed by Takeda Pharmaceutical Company. It is a selective, oral, small-molecule inhibitor of the enzyme FGF19 (Fibroblast Growth Factor 19), which plays a role in regulating bile acid synthesis and metabolism. TAK-075 is being studied for its potential to treat diseases related to bile acid dysregulation, such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). By inhibiting FGF19, TAK-075 aims to normalize bile acid levels and improve liver function.

Chemical Structure

TAK-075

CAS#667931-33-1

Theoretical Analysis

MedKoo Cat#: 145751

Name: TAK-075

CAS#: 667931-33-1

Chemical Formula: C36H46N4O4S

Exact Mass: 630.3200

Molecular Weight: 630.85

Elemental Analysis: C, 68.54; H, 7.35; N, 8.88; O, 10.14; S, 5.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TAK-075; TAK075; TAK 075;

IUPAC/Chemical Name

(R)-N-(3-(4-ethylphenyl)pentan-3-yl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 4-methylbenzenesulfonate

InChi Key

NDWLAPXXXCPRNP-GJFSDDNBSA-N

InChi Code

1S/C29H38N4O.C7H8O3S/c1-7-21-15-17-23(18-16-21)29(8-2,9-3)31-27(34)25-20(4)32-33-26(25)30-24(19-28(33,5)6)22-13-11-10-12-14-22;1-6-2-4-7(5-3-6)11(8,9)10/h10-18,24,30H,7-9,19H2,1-6H3,(H,31,34);2-5H,1H3,(H,8,9,10)/t24-;/m1./s1

SMILES Code

CC1=CC=C(C=C1)S(O)(=O)=O.CCC2=CC=C(C=C2)C(CC)(CC)NC(=O)C3=C4N[C@H](CC(C)(C)N4N=C3C)C5=CC=CC=C5

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 630.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yoshida M, Mori A, Morimoto S, Kotani E, Oka M, Notoya K, Makino H, Ono M, Shirasaki M, Tada N, Fujita H, Ban J, Ikeda Y, Kawamoto T, Goto M, Kimura H, Baba A, Yasuma T. Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4 ,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent. Bioorg Med Chem. 2011 Mar 15;19(6):1881-94. doi: 10.1016/j.bmc.2011.02.001. Epub 2011 Feb 24. PMID: 21353570.